Synonyms containing nuron biotech
We've found 105 synonyms:
Activa is a proprietary brand under Kino Biotech Co. Ltd., a public listed company in the Taiwan's GreTai Securities Market (GTSM) with its head office in Singapore. Kino Biotech Co. Ltd. owns 100% stakes in Kino Life Science Ltd, TRN Marketing (M) Sdn. Bhd. and TRN Marketing Pte. Ltd. The Taiwan's GTSM database of public listed companies states that Kino Biotech Co. Ltd. has over 4500 points of sales in China, Singapore, Malaysia, Vietnam, Thailand and Indonesia. Their core brands distributed are Kinohimitsu, Activa and Xpertise. Kino Biotech Co. Ltd. offers beauty and wellness solutions combining both external and internal uses. The Activa brand approaches skin's wellness and beauty (topical use) through natural ingredients. Whereas, its Kinohimitsu brand targets beauty solution from within our body system. Other global beauty players that offer such external and internal beauty and wellness solutions are Shishedo, Meiji and DHC brands. Activa is distributed in malls similar to other players such as ROC and Avene. The channel of distributions include beauty salons, and pharmacies such as Watson, Century, Sasa.
Cottonseed oil is a cooking oil extracted from the seeds of cotton plants of various species, mainly Gossypium hirsutum and Gossypium herbaceum, that are grown for cotton fiber, animal feed, and oil. In 2011 cotton was the third biggest of the genetically modified crops grown worldwide, as measured by acreage: soybean was 47%, occupying 75.4 million hectares; biotech maize, biotech cotton and biotech canola Cotton seed has a similar structure to other oilseeds such as sunflower seed, having an oil-bearing kernel surrounded by a hard outer hull; in processing, the oil is extracted from the kernel. Cottonseed oil is used for salad oil, mayonnaise, salad dressing, and similar products because of its flavor stability.
Axial Biotech, Inc. is a privately held molecular diagnostics company. Based in Salt Lake City, Utah, it was founded in 2002 by a group of internationally recognized spine surgeons and geneticists. The company's mission is to deliver diagnostics that improve and personalize the treatment of spine disorders. Axial Biotech conducts genetic research on scoliosis and degenerative disc disease. In September 2009, Axial Biotech announced the commercial launch of the ScoliScore AIS Prognostic Test. ScoliScore is the first DNA-based diagnostic test for scoliosis.
Biopure Corporation was a biopharmaceutical company that specialized in oxygen therapeutics (blood substitutes) for both human and veterinary use. The company developed, manufactured, and marketed oxygen therapeutics, designed to transport oxygen to the body's tissues. The oxygen technology uses hemoglobin-based oxygen carrying molecules in solution (HBOCs) to increase oxygen transfer to the tissues. The competing companies with Biopure were Allied Pharmaceutical, Northfield Laboratories, Baxter International and Hemosol of Toronto. The company developed two products: Hemopure (HBOC-1) [hemoglogin glutamer-250 (bovine)] for human use, and Oxyglobin (HBOC-301) [hemoglobin glutamer-200 (bovine)] for veterinary use. As of April 2001, Hemopure was approved for commercial sale in South Africa for treatment of acute anemia in general surgery. However, Hemopure has not been able to gain approval in the U.K. or the U.S. because of safety and reliability concerns of the European Commission and the U.S. Food and Drug Administration (FDA) respectively. The company formed an agreement with the U.S. Navy to aid in preclinical testing of Hemopure for out-of-hospital treatment of trauma patients in hemorrhagic shock. Oxyglobin is the only oxygen therapeutic approved for treatment of canine anemia in both Europe and the U.S. and has been used in treatment for thousands of cases. Unable to obtain FDA approval for Hemopure to date, Biopure ceased operations in 2009 and its assets were purchased by OPK Biotech LLC in September 2009. On July 16, 2009 Biopure announced it had filed for bankruptcy protection under Chapter 11, Title 11, United States Code and entered into an agreement with OPK Biotech LLC for the sale of substantially all of its assets.The company held nearly 30 patents relating to its oxygen therapeutics. Their patented and proprietary oxygen technology utilizes blood from cattle to develop the "hemoglobin-based" oxygen carrier rather than blood from humans. Most importantly, the issue of blood type matching is eliminated due to the "universal" nature of this oxygen therapeutic. The products are administered intravenously to deliver oxygen to the body's tissue through the formulated composition of purified hemoglobin from cattle blood and a balanced salt solution.In Hemopure, the average oxygen content is maximized due to the reduced size of the stabilized HBOC molecules in comparison to red blood cells (RBCs). Oxyglobin primarily differs from Hemopure in molecule size of the stabilized HBOC. Oxyglobin is approved for oxygen fluid therapy and an alternative to RBC transfusion in dogs, and is administered intravenously as well. The stabilized HBOC then flows through the blood plasma in the body, where oxygen transport takes place. Due to the reduced size of the HBOC in Hemopure, oxygen can be transported to restricted areas where normal RBCs fail to reach. Another advantage of this patented oxygen technology is the increased shelf life of 36 months through storage conditions at room temperature, while RBCs must be refrigerated and discarded if not used after six weeks. However, these products are only indicated for temporary oxygen replenishment through the oxygen bridge, with an average half-life of 19 hours (specifically Hemopure), therefore long term oxygen support requires RBC blood transfusion.
Basic Research is an herbal supplement and cosmetics manufacturer formed in 1993, based in Salt Lake City, Utah that distributes products through a large number of subsidiaries. In addition, their products are sold domestically and internationally through a number of high-end retailers. Dennis Gay is the president and chief executive officer of Basic Research. Basic Research has also been known to conduct business as Silver Sage, and as The Carter-Reed Company. Subsidiaries of the company include "Sanmedica International", which markets the popular Serovital-HGH and "Zoller Laboratories" markets the Zantrex-3 energy/weight-loss product. "Dynakor Pharmacal" claims to be a Russian company that manufactures the weight-loss products Formula9 and AKAVAR 20/50. These subsidiaries are all housed in the same complex in the International Center, a business park west of the SLC international airport and are simply used as a means to market different products to different demographics. Other brands include Bremenn Labs, Covaxil, Dermafactor, Ni Gen Biotech, Novex Biotech and Thincare. Over 60 products are marketed, manufactured and distributed from the lone Salt Lake City location of Basic Research.
Nuron Biotech Inc. develops specialty biologics and vaccines. Its product pipeline comprises central nervous system products, such as NU100, a recombinant human interferon beta-1b for the treatment of relapsing remitting multiple sclerosis; wound healing products, including NU200, a recombinant human epidermal growth factor product for healing diabetic foot ulcers and burns; and HibTITER, a conjugate vaccine. The company was founded in 2010 and is based in Exton, Pennsylvania.
Bullet Biotechnology is an innovative biotech company developing powerful products which will train a patient’s own immune system to fight disease.The first disease in Bullet Biotech’s crosshairs is B-cell lymphoma. Bullet Biotech’s personalized product very precisely targets a unique marker present on all B cells. The theory that a patient's immune system can be trained to safely target this marker, the idiotype protein, has been proven by decades of research at places like Stanford and the NIH. In addition to successful research, approved products such as Provenge and Yervoy - products that activate the immune system to effectively fight cancer - hint at the pivotal role immunotherapy will play in the future treatment of cancer.Bullet Biotech's experienced management team is taking a practical approach to building and realizing value for patients and investors.
Aduro BioTech, Inc., a development stage biopharmaceutical company, engages in the development of early stage cancer therapies. The company focuses on the development of its minimally invasive NT and TNT cancer treatment systems, which use iron oxide nano-particles that generate heat when exposed to an externally applied magnetic field and kills tumor cells without the toxicity or collateral damage. It offers therapies for breast, prostate, colorectal, lung, pancreas, ovarian, and head and neck cancers. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.
|Benson Hill Biosystems|
Benson Hill Biosystems
Boosting crop yields on existing acreage and with limited inputs is the foremost challenge in sustainable production agriculture. With the global population projected to reach nine billion by 2050, agricultural output must increase by 70% in this timeframe. As nations such as the United States pursue agriculture-intensive energy policies, demand and price volatility for agriculture commodities will continue to intensify. Diminishing agricultural resources such as arable land and fresh water will further compound this challenge.In the last twenty years, crop yields have improved from intensive breeding programs, increased planting densities, and biotech traits such as insect resistance and herbicide tolerance. However, blockbuster trait releases in recent years are only having single digit percentage impacts on yield. At a time when step changes are needed in crop productivity, yields are plateauing.One contributing factor to the decline in crop development is that nearly all commercial biotech traits are single-gene approaches to protecting yield. But to realize step changes and avoid a yield plateau, we must innovate beyond single-gene approaches to protecting yield, and realize step wise gains by increasing intrinsic yield.Benson Hill is dedicated to delivering substantial production gains to the agriculture sector by advancing biotech-based traits to increase intrinsic yield.
Bovine somatotropin or bovine somatotrophin (abbreviated bST and BST), or bovine growth hormone (BGH), is a peptide hormone produced by cows' pituitary glands. Like other hormones, it is produced in small quantities and is used in regulating metabolic processes. After the biotech company Genentech discovered and patented the gene for BST in the 1970s, it became possible to synthesize the hormone using recombinant DNA technology to create recombinant bovine somatotropin (rBST), recombinant bovine growth hormone (rBGH), or artificial growth hormone. Four large pharmaceutical companies, Monsanto, American Cyanamid, Eli Lilly, and Upjohn, developed commercial rBST products and submitted them to the US Food and Drug Administration (FDA) for approval. Monsanto was the first firm to receive approval. Other countries (Mexico, Brazil, India, Russia, and at least ten others) also approved rBST for commercial use. Monsanto licensed Genentech's patent, and marketed their product as "Posilac". In October 2008, Monsanto sold this business, in full, to Eli Lilly and Company for $300 million plus additional consideration.rBST has not been allowed on the market in Canada, Australia, New Zealand, Japan, Israel, or the European Union since 2000. Argentina also banned the use of rBST. The FDA, World Health Organization, and National Institutes of Health have independently stated that dairy products and meat from BST-treated cows are safe for human consumption. In the United States, public opinion led some manufacturers and retailers to market only milk that is rBST-free.A European Union report on the animal welfare effects of rBST states that its use often results in "severe and unnecessary pain, suffering and distress" for cows, "associated with serious mastitis, foot disorders and some reproductive problems".
The Almac Group is an established contract development and manufacturing organisation that provides an extensive range of integrated services to the pharmaceutical and biotech sectors globally. The services range from R&D, biomarker discovery and development, API manufacture, formulation development, clinical trial supply, IXRS® technology (IVRS/IWRS) through to commercial-scale manufacture. The international company is a privately owned organisation that has organically grown over 40 years and now employs in excess of 4,500 highly skilled personnel. Almac is headquartered in Craigavon, Northern Ireland, with operations in the UK, Ireland, across the US (Pennsylvania, North Carolina and California) and in Asia (Singapore and Tokyo). Almac's service areas include: Diagnostics, API Services and Chemical Development, Formulation Development, Clinical Services, Clinical Technologies and Commercial services.
Sorona is DuPont's brand of triexta (polytrimethylene terephthalate). It was named and commercialized in 2000. The fibers are claimed to be both soft and extremely stain resistant, while exhibiting high strength and stiffnessSorona is a co-polymer of 1,3-propanediol (obtained by fermentation) and petroleum-derived terephthalic acid (TPA) or dimethyl terephthalate (DMT). Related polymers in this series include polyethylene terephthalate (2GT) and polybutylene terephthalate (polytetramethylene terephthalate) (4GT).The polymer Sorona has been mentioned by J. Craig Venter in interviews as an example of an application of industrial biotechnology. He was quoted as saying, "DuPont argues that Sorona is going to be the first billion-dollar biotech product other than a pharmaceutical." The renewable resource content of Sorona is 37% by weight. DuPont won a 2003 Presidential Green Chemistry Challenge Award for their development of the fermentation process for production of 1,3-propanediol from corn-derived glucose in recombinant Escherichia coli K-12.
CropDesign is a biotech company located in Ghent, Belgium. The company develops a portfolio of agronomic traits for the global commercial seed markets. It has developed a technology platform to discover genetic traits for the improvement of corn, rice and other plants. Current Managing Director is Juergen Logemann.
Daratumumab (trade name Darzalex) is an anti-cancer drug. It binds to CD38, which multiple myeloma cells overexpress. Daratumumab was originally developed by Genmab, but it is now being jointly developed by Genmab along with the Johnson & Johnson subsidiary Janssen Biotech, which acquired worldwide commercialization rights to the drug from Genmab.Daratumumab was given breakthrough therapy drug status in 2013 for multiple myeloma. It was awarded orphan drug status for multiple myeloma, diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma.
Arenicins are a group of antimicrobial peptides being studied to combat Gram-negative bacteria. The arenicin family consists of three different peptides: arenicin-1, arenicin-2, and the most recently discovered, arencin-3.Given the growing acquisition of multidrug resistance among bacterial pathogens, particularly in Gram-negative bacteria, the development of arenicin as a novel drug treatment has been under way. Arenicin-3 has been of particular interest in the fight against urinary tract infections caused by E. coli strains. It is also being developed with the intention of treating hospital acquired infections. In both applications, there are two proposed modes of action by which arenicin-3 interacts with the bacteria.Adenium Biotech currently remains in the preclinical testing period of their product, arenicin-3. Toxicology, drug efficacy, and other information have yet to be determined with further research completed in clinical settings. However, with Gram-negative bacteria causing 65% of hospital-acquired infections, the commercial market for arenicin is large.